Aceragen Acquires Potential Oral Antibiotic for CF Pulmonary Flares

Aceragen reached an agreement to acquire Arrevus, including its late-stage clinical program of ARV-1801 נnow called ACG-721 נan experimental oral therapy for pulmonary exacerbations in cystic fibrosis (CF) patients. Aceragen is planning to launch a Phase 2/3 clinical trial in the second half of 2022 to evaluate ACG-721ҳೡfety and effectiveness in CF patients [ŝThe post Aceragen Acquires Potential Oral Antibiotic for CF Pulmonary Flares appeared first on Cystic Fibrosis News Today